%�쏢 0000096791 00000 n Sweets syndrome (acute febrile neutrophilic dermatosis)Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post marketing experience. Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.Filgrastim may be given as a daily subcutaneous injection or as a daily intravenous infusion diluted in 5% glucose solution given over 30 minutes (see section 6.6). Overall, reports were more common after IV administration. Consideration should be given to temporary discontinuation or dose reduction of filgrastim in patients with severe chronic neutropenia who develop thrombocytopenia (platelet count < 100 x 10As with all therapeutic proteins, there is a potential for immunogenicity. <> There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated.It is unknown whether filgrastim/metabolites are excreted in human milk. These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4).Cutaneous vasculitis has been reported in patients treated with filgrastim. Only clear solutions without particles should be used.Accidental exposure to freezing temperatures does not adversely affect the stability of filgrastim.Zarzio contains no preservative. A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.

Nevertheless, a risk of promotion of a malignant myeloid clone cannot be excluded. The only consistently reported adverse event was musculoskeletal pain‚ which is no different from the experience in the adult population.There is insufficient data to further evaluate filgrastim use in paediatric subjects.No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared to younger adult (> 18 years of age) subjects receiving cytotoxic chemotherapy and clinical experience has not identified differences in the responses between elderly and younger adult patients. While maintaining pressure on the plunger, remove the syringe from the patient. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia. This site uses cookies. Filgrastim dosing should be maintained until the last leukapheresis.The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5 MU/kg/day (5 μg/kg/day) from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.

Mais personnellement bien avant leur décision, j'étais déjà dans un système prévu pour du stockage. 193 0 obj 0000002366 00000 n Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UKTo bookmark a medicine you must sign up and log in.To view the changes to a medicine you must sign up and log in. This should be considered when interpreting bone-imaging results.Aortitis has been reported after G-CSF administration in healthy subjects and in cancer patients. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 - 2 days, and to normal levels within 1 - 7 days.Use of filgrastim in patients undergoing cytotoxic chemotherapy leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia.